Evolent Health, Inc. announced it is reiterating its second-quarter 2025 Adjusted EBITDA guidance of $33 million to $40 million and its full-year Adjusted EBITDA guidance of $135 million to $165 million. The company noted that oncology cost trends through May have remained below expectations for 2025.
Evolent also secured a Commitment Letter with Ares Management Credit funds, providing the option to borrow additional non-dilutive capital. This financing is intended to address its 2025 Convertible Notes and support incremental working capital needs associated with future growth.
Furthermore, the company reported a significant increase in its forecast for new revenue bookings going into 2026, driven by accelerating business development activities. This indicates a robust pipeline and potential for future organic growth, reinforcing confidence in Evolent's long-term strategic trajectory.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.